[1]
|
Parkin, D.M. (2004) International Variation. Oncogene, 23, 6329-6340. https://doi.org/10.1038/sj.onc.1207726
|
[2]
|
Hatakeyama, M. and Higashi, H. (2005) Helicobacter Pylori CagA: A New Paradigm for Bacterial Carcinogenesis. Cancer Science, 96, 835-843. https://doi.org/10.1111/j.1349-7006.2005.00130.x
|
[3]
|
Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., El Ghissassi, F., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L. and Cogliano, V. (2009) A Review of Human Carcinogens—Part B: Biological Agents. The Lancet Oncology, 10, 321-322. https://doi.org/10.1016/s1470-2045(09)70096-8
|
[4]
|
IARC (2012) A Review of Human Carcinogens. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 100, 1-441.
|
[5]
|
Ito, M., Takata, S., Tatsugami, M., Wada, Y., Imagawa, S., Matsumoto, Y., Takamura, A., Kitamura, S., Matsuo, T., Tanaka, S., Haruma, K. and Chayama, K. (2009) Clinical Prevention of Gastric Cancer by Helicobacter Pylori Eradication Therapy: A Systematic Review. Journal of Gastroenterology, 44, 365-371. https://doi.org/10.1007/s00535-009-0036-8
|
[6]
|
Kato, M., Asaka, M., Ono, S., Nakagawa, M., Nakagawa, S., Shimizu, Y., Chuma, M., Kawakami, H., Komatsu, Y., Hige, S. and Takeda, H. (2007) Eradication of Helicobacter Pylori for Primary Gastric Cancer and Secondary Gastric Cancer after Endoscopic Mucosal Resection. Journal of Gastroenterology, 42, 16-20. https://doi.org/10.1007/s00535-006-1928-5
|
[7]
|
Lee, Y.C., Chiang, T.H., Chou, C.K., Tu, Y.K., Liao, W.C., Wu, M.S. and Graham, D.Y. (2016) Association between Helicobacter Pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-Analysis. Gastroenterology, 150, 1113-1124. https://doi.org/10.1053/j.gastro.2016.01.028
|
[8]
|
Ma, J.L., Zhang, L., Brown, L.M., Li, J.Y., Shen, L., Pan, K.F., Liu, W.D., Hu, Y., Han, Z.X., Crystal-Mansour, S., Pee, D., Blot, W.J., Fraumeni, J.F., Jr., You, W.C. and Gail, M.H. (2012) Fifteen-Year Effects of Helicobacter Pylori, Garlic, and Vitamin Treatments on Gastric Cancer Incidence and Mortality. Journal of the National Cancer Institute, 104, 488-492. https://doi.org/10.1093/jnci/djs003
|
[9]
|
Mabe, K., Takahashi, M., Oizumi, H., Tsukuma, H., Shibata, A., Fukase, K., Matsuda, T., Takeda, H. and Kawata, S. (2009) Does Helicobacter Pylori Eradication Therapy for Peptic Ulcer Prevent Gastric Cancer. World Journal of Gastroenterology, 15, 4290-4297. https://doi.org/10.3748/wjg.15.4290
|
[10]
|
Take, S., Mizuno, M., Ishiki, K., Hamada, F., Yoshida, T., Yokota, K., Okada, H. and Yamamoto, K. (2015) Seventeen-Year Effects of Eradicating Helicobacter Pylori on the Prevention of Gastric Cancer in Patients with Peptic Ulcer; a Prospective Cohort Study. Journal of Gastroenterology, 50, 638-644. https://doi.org/10.1007/s00535-014-1004-5
|
[11]
|
Kobayashi, I., Murakami, K., Kato, M., Kato, S., Azuma, T., Takahashi, S., Uemura, N., Katsuyama, T., Fukuda, Y., Haruma, K., Nasu, M. and Fujioka, T. (2007) Changing Antimicrobial Susceptibility Epidemiology of Helicobacter pylori Strains in Japan between 2002 and 2005. Journal of Clinical Microbiology, 45, 4006-4010. https://doi.org/10.1128/JCM.00740-07
|
[12]
|
Murakami, K., Sakurai, Y., Shiino, M., Funao, N., Nishimura, A. and Asaka, M. (2016) Vonoprazan, a Novel Potassium-Competitive Acid Blocker, as a Component of First-Line and Second-Line Triple Therapy for Helicobacter pylori Eradication: A Phase III, Randomised, Double-Blind Study. Gut, 65, 1439-1446. https://doi.org/10.1136/gutjnl-2015-311304
|
[13]
|
Nishizawa, T., Maekawa, T., Watanabe, N., Harada, N., Hosoda, Y., Yoshinaga, M., Yoshio, T., Ohta, H., Inoue, S., Toyokawa, T., Yamashita, H., Saito, H., Kuwai, T., Katayama, S., Masuda, E., Miyabayashi, H., Kimura, T., Nishizawa, Y., Takahashi, M. and Suzuki, H. (2015) Clarithromycin versus Metronidazole as First-Line Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Controlled Study in Japan. Journal of Clinical Gastroenterology, 49, 468-471.
|
[14]
|
Chemotherapy, J.S.F. (2000) Antimicrobial Susceptibility Subcommittee on Helicobacter pylori MIC Breakpoints for Clarithromycin and Amoxicillin. Japan Society of Chemotherapy, 48, 561-567.
|
[15]
|
Testing, E.C.A.S. (2017) Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 7.0 ed.
|
[16]
|
Fukase, K., Kato, M., Kikuchi, S., Inoue, K., Uemura, N., Okamoto, S., Terao, S., Amagai, K., Hayashi, S. and Asaka, M. (2008) Effect of Eradication of Helicobacter pylori on Incidence of Metachronous Gastric Carcinoma after Endoscopic Resection of Early Gastric Cancer: An Open-Label, Randomised Controlled Trial. The Lancet, 372, 392-397.
|
[17]
|
Gisbert, J.P., Khorrami, S., Carballo, F., Calvet, X., Gene, E. and Dominguez-Munoz, E. (2004) Meta-Analysis: Helicobacter pylori Eradication Therapy vs. Antisecretory Non-Eradication Therapy for the Prevention of Recurrent Bleeding from Peptic Ulcer. Alimentary Pharmacology & Therapeutics, 19, 617-629. https://doi.org/10.1111/j.1365-2036.2004.01898.x
|
[18]
|
Wong, B.C., Lam, S.K., Wong, W.M., Chen, J.S., Zheng, T.T., Feng, R.E., Lai, K.C., Hu, W.H., Yuen, S.T., Leung, S.Y., Fong, D.Y., Ho, J., Ching, C.K. and Chen, J.S. (2004) Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China: A Randomized Controlled Trial. JAMA, 291, 187-194. https://doi.org/10.1001/jama.291.2.187
|
[19]
|
Correa, P., Fontham, E.T., Bravo, J.C., Bravo, L.E., Ruiz, B., Zarama, G., Realpe, J. L., Malcom, G.T., Li, D., Johnson, W.D. and Mera, R. (2000) Chemoprevention of Gastric Dysplasia: Randomized Trial of Antioxidant Supplements and Anti-Helicobacter pylori Therapy. Journal of the National Cancer Institute, 92, 1881-1888. https://doi.org/10.1093/jnci/92.23.1881
|
[20]
|
Iijima, K., Ohara, S., Sekine, H., Koike, T., Kato, K., Asaki, S., Shimosegawa, T. and Toyota, T. (2000) Changes in Gastric Acid Secretion Assayed by Endoscopic Gastrin Test before and after Helicobacter pylori Eradication. The Gut, 46, 20-26. https://doi.org/10.1136/gut.46.1.20
|
[21]
|
Kang, J.M., Kim, N., Shin, C.M., Lee, H.S., Lee, D.H., Jung, H.C. and Song, I.S. (2012) Predictive Factors for Improvement of Atrophic Gastritis and Intestinal Metaplasia after Helicobacter pylori Eradication: A Three-Year Follow-Up Study in Korea. Helicobacter, 17, 86-95. https://doi.org/10.1111/j.1523-5378.2011.00918.x
|
[22]
|
Kato, M., Terao, S., Adachi, K., Nakajima, S. ando, T., Yoshida, N., Uedo, N., Murakami, K., Ohara, S., Ito, M., Uemura, N., Shimbo, T., Watanabe, H., Kato, T. and Ida, K. (2013) Changes in Endoscopic Findings of Gastritis after Cure of H. pylori Infection: Multicenter Prospective Trial. Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society, 25, 264-273.
|
[23]
|
Kodama, M., Murakami, K., Okimoto, T., Sato, R., Uchida, M., Abe, T., Shiota, S., Nakagawa, Y., Mizukami, K. and Fujioka, T. (2012) Ten-Year Prospective Follow-Up of Histological Changes at Five Points on the Gastric Mucosa as Recommended by the Updated Sydney System after Helicobacter pylori Eradication. Journal of Gastroenterology, 47, 394-403. https://doi.org/10.1007/s00535-011-0504-9
|
[24]
|
Ohkusa, T., Fujiki, K., Takashimizu, I., Kumagai, J., Tanizawa, T., Eishi, Y., Yokoyama, T. and Watanabe, M. (2001) Improvement in Atrophic Gastritis and Intestinal Metaplasia in Patients in Whom Helicobacter pylori Was Eradicated. Annals of Internal Medicine, 134, 380-386. https://doi.org/10.7326/0003-4819-134-5-200103060-00010
|
[25]
|
Rokkas, T., Pistiolas, D., Sechopoulos, P., Robotis, I. and Margantinis, G. (2007) The Long-Term Impact of Helicobacter pylori Eradication on Gastric Histology: A Systematic Review and Meta-Analysis. Helicobacter, 12, 32-38. https://doi.org/10.1111/j.1523-5378.2007.00563.x
|
[26]
|
Sung, J.J., Lin, S.R., Ching, J.Y., Zhou, L.Y., To, K.F., Wang, R.T., Leung, W.K., Ng, E.K., Lau, J.Y., Lee, Y.T., Yeung, C.K., Chao, W. and Chung, S.C. (2000) Atrophy and Intestinal Metaplasia One Year after Cure of H. pylori Infection: A Prospective, Randomized Study. Gastroenterology, 119, 7-14. https://doi.org/10.1053/gast.2000.8550
|
[27]
|
Wang, J., Xu, L., Shi, R., Huang, X., Li, S.W., Huang, Z. and Zhang, G. (2011) Gastric Atrophy and Intestinal Metaplasia before and after Helicobacter pylori Eradication: A Meta-Analysis. Digestion, 83, 253-260. https://doi.org/10.1159/000280318
|
[28]
|
Watanabe, H., Yamaguchi, N., Kuwayama, H., Sekine, C., Uemura, N., Kaise, M., Nakamura, T., Kubo, M., Yoshida, S., Haruma, K., Inoue, M., Shimatani, T., Sanuki, E., Mieno, H., Kawanishi, M., Nakazawa, S. and Tanaka, T. (2003) Improvement in Gastric Histology Following Helicobacter pylori Eradication Therapy in Japanese Peptic Ulcer Patients. The Journal of International Medical Research, 31, 362-369. https://doi.org/10.1177/147323000303100502
|
[29]
|
Maehata, Y., Nakamura, S., Fujisawa, K., Esaki, M., Moriyama, T., Asano, K., Fuyuno, Y., Yamaguchi, K., Egashira, I., Kim, H., Kanda, M., Hirahashi, M. and Matsumoto, T. (2012) Long-Term Effect of Helicobacter pylori Eradication on the Development of Metachronous Gastric Cancer after Endoscopic Resection of Early Gastric Cancer. Gastrointestinal Endoscopy, 75, 39-46.
|
[30]
|
Masuyama, H., Yoshitake, N., Sasai, T., Nakamura, T., Masuyama, A., Zuiki, T., Kurashina, K., Mieda, M., Sunada, K., Yamamoto, H., Togashi, K., Terano, A. and Hiraishi, H. (2015) Relationship between the Degree of Endoscopic Atrophy of the Gastric Mucosa and Carcinogenic Risk. Digestion, 91, 30-36. https://doi.org/10.1159/000368807
|
[31]
|
Take, S., Mizuno, M., Ishiki, K., Nagahara, Y., Yoshida, T., Yokota, K. and Oguma, K. (2007) Baseline Gastric Mucosal Atrophy Is a Risk Factor Associated with the Development of Gastric Cancer after Helicobacter pylori Eradication Therapy in Patients with Peptic Ulcer Diseases. Journal of Gastroenterology, 42, 21-27. https://doi.org/10.1007/s00535-006-1924-9
|
[32]
|
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N. and Schlemper, R.J. (2001) Helicobacter pylori Infection and the Development of Gastric Cancer. The New England Journal of Medicine, 345, 784-789. https://doi.org/10.1056/NEJMoa001999
|
[33]
|
Kato, S., Kikuchi, S. and Nakajima, S. (2008) When Does Gastric Atrophy Develop in Japanese chIldren? Helicobacter, 13, 278-281. https://doi.org/10.1111/j.1523-5378.2008.00611.x
|
[34]
|
Obayashi, N., Ohtsuka, Y., Hosoi, K., Ikuse, T., Jimbo, K., Aoyagi, Y., Fujii, T., Kudo, T., Asaoka, D., Hojo, M., Nagahara, A., Watanabe, S. and Shimizu, T. (2016) Comparison of Gene Expression between Pediatric and Adult Gastric Mucosa with Helicobacter pylori Infection. Helicobacter, 21, 114-123. https://doi.org/10.1111/hel.12245
|
[35]
|
Sugano, K., Tack, J., Kuipers, E.J., Graham, D.Y., El-Omar, E.M., Miura, S., Haruma, K., Asaka, M., Uemura, N. and Malfertheiner, P. (2015) Kyoto Global Consensus Report on Helicobacter pylori Gastritis. Gut, 64, 1353-1367. https://doi.org/10.1136/gutjnl-2015-309252
|
[36]
|
Hashinaga, M., Okimoto, T., Kodama, M., Mizukami, K., Ogawa, R., Okamoto, K., Shutou, M., Fukuda, K., Sonoda, A., Fukuda, M., Honda, S., Yamaoka, Y. and Murakami, K. (2016) Drug Resistance in Japan; The Presesnt Status of Helicobacter pylori; The Totaled Results of the Resistant Strain Survey in 2013 and 2014, Wagakunini okeru yakuzaitaisei Helicobacter pylori no Genjo—2013-2014 nendo taiseikin surveillance no syuukei houkoku. Japanese Journal of Helicobacter Research, 17, 45-49.
|
[37]
|
Kato, S. and Fujimura, S. (2010) Primary Antimicrobial Resistance of Helicobacter pylori in Children during the Past 9 Years. Pediatrics International, 52, 187-190. https://doi.org/10.1111/j.1442-200X.2009.02915.x
|
[38]
|
Kato, S., Fujimura, S., Udagawa, H., Shimizu, T., Maisawa, S., Ozawa, K. and Iinuma, K. (2002) Antibiotic Resistance of Helicobacter pylori Strains in Japanese Children. Journal of Clinical Microbiology, 40, 649-653. https://doi.org/10.1128/JCM.40.2.649-653.2002
|
[39]
|
Kato, S., Konno, M., Maisawa, S., Tajiri, H., Yoshimura, N., Shimizu, T., Toyoda, S., Nakayama, Y. and Iinuma, K. (2004) Results of Triple Eradication Therapy in Japanese Children: A Retrospective Multicenter Study. Journal of Gastroenterology, 39, 838-843. https://doi.org/10.1007/s00535-004-1398-6
|
[40]
|
Okamura, T., Suga, T., Nagaya, T., Arakura, N., Matsumoto, T., Nakayama, Y. and Tanaka, E. (2014) Antimicrobial Resistance and Characteristics of Eradication Therapy of Helicobacter pylori in Japan: A Multi-Generational Comparison. Helicobacter, 19, 214-220. https://doi.org/10.1111/hel.12124
|
[41]
|
Okuda, M., Kikuchi, S., Mabe, K., Osaki, T., Kamiya, S., Fukuda, Y. and Kato, M. (2017) Nationwide Survey of Helicobacter pylori Treatment for Children and Adolescents in Japan. Pediatrics International, 59, 57-61. https://doi.org/10.1111/ped.13038
|
[42]
|
Glupczynski, Y. (1998) Antimicrobial Resistance in Helicobacter pylori: A Global Overview. Acta Gastro-Enterologica Belgica, 61, 357-366. https://doi.org/10.1007/978-94-011-4882-5_42
|
[43]
|
Kim, J.J., Reddy, R., Lee, M., Kim, J.G., El-Zaatari, F.A., Osato, M.S., Graham, D.Y. and Kwon, D.H. (2001) Analysis of Metronidazole, Clarithromycin and Tetracycline Resistance of Helicobacter pylori Isolates from Korea. Journal of Antimicrobial Chemotherapy, 47, 459-461. https://doi.org/10.1093/jac/47.4.459
|
[44]
|
Ueki, N., Miyake, K., Kusunoki, M., Shindo, T., Kawagoe, T., Futagami, S., Tsukui, T., Inagaki, H. and Sakamoto, C. (2009) Impact of Quadruple Regimen of Clarithromycin Added to Metronidazole-Containing Triple Therapy against Helicobacter pylori Infection Following Clarithromycin-Containing Triple-Therapy Failure. Helicobacter, 14, 91-99. https://doi.org/10.1111/j.1523-5378.2009.00664.x
|
[45]
|
Graham, D.Y., Lu, H. and Yamaoka, Y. (2007) A Report Card to Grade Helicobacter pylori Therapy. Helicobacter, 12, 275-278. https://doi.org/10.1111/j.1523-5378.2007.00518.x
|
[46]
|
Sugimoto, M., Uotani, T., Sahara, S., Ichikawa, H., Yamade, M., Sugimoto, K. and Furuta, T. (2014) Efficacy of Tailored Helicobacter pylori Eradication Treatment Based on Clarithromycin Susceptibility and Maintenance of Acid Secretion. Helicobacter, 19, 312-318. https://doi.org/10.1111/hel.12128
|
[47]
|
Koletzko, S., Jones, N.L., Goodman, K.J., Gold, B., Rowland, M., Cadranel, S., Chong, S., Colletti, R.B., Casswall, T., Elitsur, Y., Guarner, J., Kalach, N., Madrazo, A., Megraud, F., Oderda, G. and H pylori Working Groups of ESPGHAN and NASPGHAN (2011) Evidence-Based Guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori Infection in Children. Journal of Pediatric Gastroenterology and Nutrition, 53, 230-243.
|
[48]
|
Kawai, T., Yamagishi, T., Yagi, K., Kataoka, M., Kawakami, K., Sofuni, A., Itoi, T., Sakai, Y., Moriyasu, F., Osaka, Y., Takagi, Y., Aoki, T., Rimbara, E., Noguchi, N. and Sasatsu, M. (2008) Tailored Eradication Therapy Based on Fecal Helicobacter pylori Clarithromycin Sensitivities. Journal of Gastroenterology and Hepatology, 23, S171-S174. https://doi.org/10.1111/j.1440-1746.2008.05408.x
|